Apollon Wealth Management LLC Makes New Investment in United Therapeutics Corporation $UTHR

Apollon Wealth Management LLC bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 13,288 shares of the biotechnology company’s stock, valued at approximately $7,880,000.

Several other hedge funds also recently made changes to their positions in the company. Torren Management LLC purchased a new stake in United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management lifted its position in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the period. WealthCollab LLC lifted its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. boosted its holdings in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics during the 4th quarter valued at $31,000. 94.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on UTHR shares. HC Wainwright increased their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Cantor Fitzgerald upped their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. UBS Group raised their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $558.40, for a total transaction of $5,584,000.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,540,358.40. The trade was a 34.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 633,218 shares of company stock worth $357,330,714. 8.60% of the stock is owned by insiders.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $544.92 on Tuesday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The business has a fifty day moving average price of $560.52 and a 200-day moving average price of $526.39. The firm has a market capitalization of $23.13 billion, a price-to-earnings ratio of 20.12, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the prior year, the firm posted $6.63 EPS. On average, equities research analysts expect that United Therapeutics Corporation will post 26.49 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.